Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — BofA-ML Global Healthcare Conference 2011
7 slides from Teva Pharmaceutical Industries's conference presentation, Sep 14, 2011
Slide 1: BofA-ML Global Healthcare Conference
BofA-ML Global Healthcare Conference Dr. Gerard van Odijk, President & CEO, Teva Europe Investor Relations London, September 14, 2011 Investor Relations 1
Slide 2: 1H 2011 results
1H 2011 results 1H/10* 1H/11* Change Sales 7,453 8,292 +11% $m Operating income 2,203 2,205 0 $m Net income 1,811 1,920 +6% $m EPS 1.99 2.14 +8% $ Cash flow from 1,840 2,224 +21% operations $m *Net income, operating income and EPS are non-GAAP results Investor Relations 2
Slide 3: Diversified business
Diversified business Sales, 2011 H1, % of total Hybrid business with Growing ex-US generic/branded split business Breakdown by product Breakdown by geography Women’s Biosimilars API Respiratory 3 1 4 Inter- 6 national 16 Innovative North 11 Generics Europe America 64 34 50 Investor Relations 3
Slide 4: On track to deliver 2015 strategic targets
On track to deliver 2015 strategic targets 2015 GENERICS Strategic Plan: ratiopharm: GX #1 in Europe Taiyo: leadership in Japan Infarmasa: expansion in LA DIVERSIFY Progress TEVA on all BRANDED fronts Cephalon: expansion/diversification Theramex: global expansion women’s health OTC JV with P&G: leve
Slide 5: No. 1 in Europe and top tier in key European countries
No. 1 in Europe and top tier in key European countries 2007 Today UK No.1 No.1 Netherlands No.1 No.1 A platform for growth Germany No.2 Italy No.1 No.1 Return on investments UP France No.3 Attractiveness to partner UP Spain No.1 Capitalize opportunities UP Hungary No.1 Poland No.3 Czech Republic No.
Slide 6: Market highlights Europe 1st half 2011
Market highlights Europe 1st half 2011 No. 1 with ~30% market share UK Two excellent quarters – proforma growth Q1 22% and Q2 29% New commercial scheme No. 2 with ~22% market share, closing the gap with No. 1 Germany Proforma growth Q1 -14% and Q2 +8% For 1st time since 2005 ratiopharm label has tak
Slide 7: Thank You
Thank You Investor Relations 7
Teva Pharmaceutical Industries — BofA-ML Global Healthcare Conference 2011 on 6ix